NCT02000050View on ClinicalTrials.gov

Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 11, 2013

Primary Completion Date

March 15, 2019

Study Completion Date

March 15, 2019

Conditions
Rectal Carcinoma
Interventions
DRUG

FOLFOX4

FOLFOX4

RADIATION

Tomotherapy

Tomotherapy

PROCEDURE

TME (Total Mesorectal Excision)

TME (Total Mesorectal Excision)

Trial Locations (2)

47014

UO Oncologia Medica IRCCS IRST, Meldola

48121

Oncologia Medica PO RAVENNA; FAENZA; LUGO, Ravenna

All Listed Sponsors
lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER

NCT02000050 - Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE) | Biotech Hunter | Biotech Hunter